By ROKU GODA/ Staff Writer
March 16, 2020 at 17:11 JST
Ryuichi Morishita, left, an Osaka University professor, speaks at a news conference in Tokyo on March 5 with Ei Yamada, president of AnGes Inc., and Junichi Mineno, an executive of Takara Bio Inc. (Roku Goda)
A drug development startup has begun working on a DNA vaccine against the new coronavirus, aiming to begin clinical trials in six months.
AnGes Inc., which was founded by an Osaka University researcher, announced in Tokyo on March 5 that the company is working with the university to develop the vaccine.
The vaccine under development will produce antibodies against the new coronavirus inside a person’s body through the use of synthetic DNA.
Proteins created by the DNA develop antibodies, which are expected to help immunize a recipient and prevent a patient’s condition from worsening.
“The advantage of a DNA vaccine is that it can be manufactured quickly,” said Ryuichi Morishita, a professor of clinical gene therapy at Osaka University who founded AnGes. “We’ll first check how many antibodies the vaccine can create in mice over two months.”
DNA vaccines can be manufactured in a span of several weeks. It takes about half a year to culture conventional vaccines, which use attenuated pathogens or those that are altered to prevent them from multiplying.
AnGes has started joint manufacturing of the DNA vaccine for the new coronavirus with Takara Bio Inc., a leading reagent company, based on its genetic information. In theory, DNA vaccines can trigger a strong immune reaction, but in some cases, the vaccines failed to fully immunize those who received vaccinations.
DNA vaccines have yet to be commercialized for human use.
However, Morishita said, “No safety concerns regarding a DNA vaccine have been confirmed in clinical trials on more than 1,400 people.”
As for the effects of DNA vaccines, he said, “In some cases, three to four vaccinations may be necessary to increase the production of antibodies. The vaccine can still be effective even if the virus mutates slightly.”
This special page portrays the dramatic arrest of Carlos Ghosn and the twists and turns that followed.
This special page reviews what the former Nissan Motor Co. chairman left during his 19 years in Japan.
Baseball star Ichiro Suzuki had much to say on March 21, the day he hung up his spikes.
This special page details how journalists uncovered shady transactions through Bermuda and other tax havens.
Here are reports about efforts in Japan and abroad to achieve the U.N. sustainable development goals.